Embed Size (px)
Citation preview
CHROMALYTICA AB 2015
Your Health in a Breath
CHROMALYTICA AB 2015
Breath analysis
VOCs are identified in breath and classified
Volatile Organic Compounds
Lungs have a surface of 100 m² Release compounds in breath
Lungs and breath
Breath analysis is a new method Fast, cost-effective and painless
New diagnostic method
One or several VOCs can be biomarkers for a disease
Disease diagnosis
CHROMALYTICA AB 2015
Early detection of diseases
No risk for contamination
Non-invasive
Cost-effective
Breath analysis key benefits
Large scale screening
No expertise required
CHROMALYTICA AB 2015
Laboratory diagnostics market
48 Billion $ in 2012
Growth 5,8%
75 Billion $ in 2020
Source: Adamant Biomedical Investments AG
US
EU
ASIA JP
OT
US
EU
ASIA
JP
OT
CHROMALYTICA AB 2015
Chromalytica’s concept: fast and simple
Test results delivered
Data uploaded to server
Breath sample collected in bag 1
4
6
Sample processed in analyser 2
VOCs identified in sample 3
VOCs matched with database 5
CHROMALYTICA AB 2015
Chromalytica’s analyzer: DUVA
Deep Ultra Violet Analyzer
CHROMALYTICA AB 2015
Bowel cancer kills 694.000 people a year. No symptoms during the first months
6 different VOCs discovered to be biomarkers for the disease
Breath analysis recognized as valid diagnostic method in several studies
Chromalytica’s case: bowel cancer
The DUVA can identify and quantify these specific VOCs in breath samples
Bowel cancer screening costs £ 77 Millions per year to NHS in UK
Chromalytica planning cross validation studies with Swedish Government
Source: WHO, NHS
CHROMALYTICA AB 2015
Chromalytica’s revenue model
Instrument DUVA
Database license fee
System service fee
Samplers (plastic bags)
Breath test results
5 sources of income
4 sources of recurrent income
Out of
CHROMALYTICA AB 2015
Chromalytica’s key business leverages
Strong cash-cow model
Continue positive cash flows
4 sources of recurrent income
Massive patient data production
High profitability at low cost
Big data profitability
Fast market adoption
Fast cash flow generation
Easily deployed
Global market
No expertise required
Easily scalable
CHROMALYTICA AB 2015
Competitive Landscape
Qualitative
analysis Quantitative
analysis Multi-disease
diagnosis
Chromalytica ✔ ✔ ✔
Menssana ✔ ✗ ✔
Aerocrine ✔ ✔ ✗
Humedics ✔ ✔ ✗
Picomole ✔ ✗ ✗
Metabolomx ✔ ✗ ✗
Isomark ✔ ✗ ✗
CHROMALYTICA AB 2015
Our Team Francesco Palmisano
Inventor, CEO of several med-tech companies, 10+ years experience in laboratory diagnostics
CEO
Thomas Pileby
Finance director, chairman of several companies, 30+ years experience in industrial operations worldwide
CFO
Heino Wendelrup
Director for Sony Mobile, head of global system engineering, 25+ years experience in IT solutions
CTO
Thomas Lundeberg
Inventor, physiology professor, founder of several stock exchange listed companies
CMO
CHROMALYTICA AB 2015
1975. The Lagesson couple starts experiments with GC-UV
1990. Several scientific studies are published
2000. Experimental setting is constructed
2010. Chromalytica incorporated at Medeon Science Park
2011. More studies on breath analysis with GC-UV
2012. Start construction of the DUVA project
2013. Construction of the DUVA completed
2013. DUVA tested at Karolinska Institutet in Stockholm
2013. DUVA tested at MAXIV particle accelerator in Lund
2014. Chromalytica awarded prize for hottest hi-tech
2015. DUVA instrument industrialized
2016. DUVA becomes a med-tech instrument
CHROMALYTICA AB 2015
Financial Projections
1.000’s of $ 2016 2017 2018 2019 2020
Sales 0 1 090 4 670 9 610 18 140
Gross Margin 0 820 3 600 7 230 13 350
Net Result -1 330 -1 130 780 3 380 7 720
Total Equity 1 700 560 1 350 4 730 12 450
Cash Flow 980 -810 750 2 900 7 040
CHROMALYTICA AB 2015
Funding Needs
R&D
Operations
IP
18 months to cash positive
3 Million $ investment
R&D, IP, Operations targets
CHROMALYTICA AB 2015
www.chromalytica.com
